Jaguar Health Granted Extension to Regain Nasdaq Compliance, Announces OnTarget Trial Results Soon

Jaguar Health, Inc. (NASDAQ:JAGX) has been given an extension until August 13, 2024, by Nasdaq to meet the $1.00 bid price requirement, crucial for maintaining its listing on The Nasdaq Capital Market. The company must achieve a closing bid price of at least $1.00 per share for ten consecutive business days before the deadline. Jaguar's CEO, Lisa Conte, expressed satisfaction with the extension, which eliminates the need for a previously scheduled hearing regarding a potential delisting.

The company is also in the near-term concluding its Phase 3 pivotal OnTarget trial, investigating crofelemer for the preventative treatment of cancer therapy-related diarrhea. Jaguar anticipates publishing the top-line results of this critical study soon. Meanwhile, Jaguar's stock will continue to be traded on Nasdaq under the symbol ‘JAGX’, as the board takes necessary steps to comply with Nasdaq's listing requirements.